articleTop 1% cited

Zygomycosis in a Tertiary‐Care Cancer Center in the Era of <i>Aspergillus‐</i> Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent Cases

The Journal of Infectious Diseases · 2005 · Vol. 191(8) · pp. 1350–1360

Dimitrios P. Kontoyiannis✉(The University of Texas MD Anderson Cancer Center)Michail S. LionakisRussell E. Lewis(University of Houston)Georgios ChamilosMimi Healy(Spectral MD (United States))C PeregoAmar SafdarHagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)Richard E. ChamplinThomas J. Walsh(National Cancer Institute)Issam Raad

View via DOI Publisher page

Abstract

Zygomycosis should be considered in immunosuppressed patients who develop sinusitis while receiving VRC prophylaxis, especially those with diabetes and malnutrition.

Antifungal resistance and susceptibility Infectious Diseases and Mycology Fungal Infections and StudiesZygomycosisVoriconazoleAntifungalTertiary careMedicineObservational studyAspergillosisIntensive care medicineMycosisCancer

MeSH terms

Antifungal AgentsAspergillosisAspergillusFemaleHumansLeukemiaMaleMiddle AgedNeoplasmsRisk FactorsCase-Control StudiesDNA FingerprintingAPACHEZygomycosisDrug Resistance, Fungal

Citations

674

FWCI

26.71

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases